Network for MS Trails

Capitalising on the strengths and experience of the leading MS Research Centers in Europe for clinical trials

Clinical trials have contributed much to the development and further improvement of treatment options for patients with MS. This significant progress has also created new opportunities and challenges. In order to capitalize on the strengths and experience of the leading MS Research Centres in Europe to better face these challenges, the Board of the European Charcot Foundation established under its auspices and in close collaboration with ECTRIMS a “European Network for MS Trials (ENMST)“.

Main aims of the European Network for MS Trials:

  • To facilitate identification and evaluation of effective agents and treatment algorithms for MS, especially in progressive MS in close collaboration with the progressive MS alliance
  • To define and harmonize standards for all aspects of MS trials
  • To establish standards for the interaction between investigators and industry and to serve as an interface for such interactions
  • To interact with health authorities at a national and supranational level

This is an open initiative, so other centres may join the initiative.

Founding Members of ENMST

  • Giancarlo Comi, Scientific Institute San Raffaele (Milan, Italy),
  • Carlo Pozzilli, Multiple Sclerosis Center, Sant’ Andrea Hospital (Rome, Italy)
  • Per Sölberg-Sörensen, Danish Multiple Sclerosis Center (Copenhagen, Denmark)
  • Catherinne Lubetzki, Salpêtrière MS Clinical Research Center (Paris, France)
  • Michel Clanet, Department of Neurology, Hôpital Pierre Paul Riquet (Toulouse, France)
  • Hans-Peter Hartung, Department of Neurology, Heinrich-Heine-University (Düsseldorf, Germany)
  • Ralf Gold, Neurologische Universitätsklinik, Sint Josef Hospital (Bochum, Germany)
  • Krzysztof Selmaj, Katedra i Klinika Neurologii AM Medical (Lodz, Poland)
  • Xavier Montalban, Multiple Sclerosis Centre of Catalonia, Vall d’Hebron University Hospital (Barcelona, Spain)
  • Oscar Fernandez, Instituto de Neurociencias Clínicas, Hospital Regional Universitario Carlos Haya (Malaga, Spain)
  • Jan Hillert,  Department of Clinical Neuroscience, Karolinska Institutet (Stockholm, Sweden)
  • Ludwig Kappos (Coordinator ENMST), Department of Neurology, University Hospital (Basel, Switzerland)
  • Eva Havrdova, MS Center, Department of Neurology, First Medical Faculty, Charles University (Prague, Czech Republic)
  • Alan Thompson, Institute of Neurology, University College London (London, United Kingdom)
  • Gavin Giovannoni, Neuroscience and Trauma Centre, Blizard Institute of Cell and Molecular Science (London, United Kingdom)
  • Jaqueline Palace, Oxford Multiple Sclerosis and Neuromyelitis Group (Oxford, United Kingdom)